RayThera, Inc. raised $110 million in Series A financing. The funding will advance their preclinical immunology pipeline and was co-led by Foresite Capital and OrbiMed Advisors.

RayThera, Inc., a recently founded biotechnology company focused on small molecule therapies in immunology, has completed its Series A financing with a total of $110 million raised. The financing was co-led by Foresite Capital and OrbiMed Advisors, with participation from TTM Capital. Proceeds will be used to advance RayThera’s lead drug candidates through Phase 1 clinical studies. The strong support from investors is instrumental for the company’s growth.